Atossa Therapeutics Inc (ATOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -17,828 | -17,240 | -11,405 | -8,123 | -6,369 |
| Depreciation Amortization | 47 | 53 | 44 | 129 | 304 |
| Accounts payable and accrued liabilities | 1,295 | -60 | 18 | 81 | -560 |
| Other Working Capital | -112 | -791 | -64 | -340 | -1,068 |
| Other Operating Activity | 5,028 | 8,910 | 2,445 | 1,659 | 2,319 |
| Operating Cash Flow | $-11,570 | $-9,128 | $-8,962 | $-6,594 | $-5,375 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -9 | -8 | -111 | N/A | -9 |
| Investing Cash Flow | $-9 | $-8 | $-111 | $N/A | $-9 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 33,619 | 11,337 | N/A | 6,912 | 4,696 |
| Other Financing Activity | 4,933 | 0 | 12,291 | 3,872 | 0 |
| Financing Cash Flow | $38,552 | $11,337 | $12,291 | $10,784 | $4,696 |
| Beginning Cash Position | 12,691 | 10,491 | 7,273 | 3,083 | 3,716 |
| End Cash Position | 39,664 | 12,691 | 10,491 | 7,273 | 3,028 |
| Net Cash Flow | $26,973 | $2,201 | $3,218 | $4,190 | $-688 |
| Free Cash Flow | |||||
| Operating Cash Flow | -11,570 | -9,128 | -8,962 | -6,594 | -5,375 |
| Capital Expenditure | -9 | -8 | -111 | N/A | -9 |
| Free Cash Flow | -11,579 | -9,136 | -9,073 | -6,594 | -5,384 |